Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page
- ChecktodayChange DetectedThe page’s footer/version label was updated to “Revision: v3.5.3,” and a related-topics section entry referencing “Bladder cancer” and “MedlinePlus Genetics” was removed.SummaryDifference0.2%

- Check8 days agoChange DetectedAdded 'Bladder cancer' and related topics including MedlinePlus Genetics, and updated the page revision from v3.5.0 to v3.5.2.SummaryDifference0.2%

- Check15 days agoChange DetectedDifference0.2%

- Check22 days agoChange DetectedAdded 'Bladder cancer' as a related topic and added 'MedlinePlus Genetics' as a related topic.SummaryDifference0.2%

- Check36 days agoChange DetectedRevision: v3.5.0 has been added and the previous Revision: v3.4.3 has been removed.SummaryDifference0.1%

- Check43 days agoChange DetectedRemoved the 'Bladder cancer' topic and the 'MedlinePlus Genetics' related topics from the page.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.